PPIDT00276
Drug Information
| Name | Alirocumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB09302 |
| Type | biotech |
| Indication | Alirocumab is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.[L50637] It is also indicated as an adjunct to diet - alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies - to reduce LDL-C in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)), adults with homozygous familial hypercholesterolemia (HoFH), and pediatric patients ≥8 years of age with HeFH.[L50637] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
150 MG
|
| Injection, solution | Parenteral; Subcutaneous |
300 MG
|
| Injection, solution | Parenteral; Subcutaneous |
75 MG
|
| Injection, solution | Subcutaneous |
150 mg/1mL
|
| Injection, solution | Subcutaneous |
300 mg
|
| Injection, solution | Subcutaneous |
75 mg/1mL
|
| Solution | Subcutaneous |
150 mg / mL
|
| Solution | Subcutaneous |
300 mg / 2 mL
|
| Solution | Subcutaneous |
75 mg / mL
|
| Injection, solution | — |
150 mg/nl
|
| Injection, solution | — |
150 mg/ml
|
| Injection, solution | — |
75 mg/ml
|
| Injection, solution | Subcutaneous |
150 mg/ml
|
| Injection, solution | Subcutaneous |
75 mg/ml
|
| Injection, solution | Subcutaneous |
150 mg
|
| Injection, solution | Subcutaneous |
75 MG
|
| Solution | Subcutaneous |
7500000 mg
|
| Solution | Subcutaneous |
15000000 mg
|
| Solution | Subcutaneous |
75.000 mg
|